Caption
Researcher in a laboratory
Funding boost for promising treatment
Date
Research news
Date
The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Date
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Date
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
Date
We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
Date
Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
Date
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
Date
We're funding a new research study into a possible treatment for hallucinations in Parkinson's.
Date
Researchers in the US have uncovered a link between long-term exposure to pollution and deterioration in health conditions. This includes Parkinson's and Alzheimer's.
Date
Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Date
Sharing the results of the 'What Matters Most?' survey and coronavirus poll that have determined our campaigning priorities for the next four years